In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis

One of the major mechanisms followed by the therapeutic agents to target the causative organism of TB, Mycobacterium tuberculosis, involves disruption of its DNA replication cycle. The process of replication involves two steps, i.e., breakage and reunion of DNA at gyrase A (GyrA) domain and ATP hydrolysis at gyrase B (GyrB) domain, both occur simultaneously. Current therapy for multi-drug resistant TB (MDR-TB) involves FDA approved, fluoroquinolone-based antibiotics, which act by targeting replication process at GyrA domain.

Source: Tuberculosis - August 8, 2018 Category: Respiratory Medicine Authors: Aanchal Kashyap, Pankaj Kumar Singh, Om Silakari Source Type: research